{
  "id": "insomnia-neurological",
  "title": "Insomnia — Neurological Approach",
  "version": "1.0",
  "icd10": [
    "** G47.00 (Insomnia",
    "unspecified)",
    "G47.01 (Insomnia due to medical condition)",
    "F51.01 (Primary insomnia)"
  ],
  "scope": "** Neurological evaluation and management of insomnia in adults with neurological conditions. Focuses on insomnia comorbid with TBI, dementia, MS, Parkinson's disease, chronic pain, epilepsy, and stroke. Covers CBT-I as first-line, pharmacotherapy selection considering neurological comorbidities, and identification of secondary causes. Excludes primary psychiatric insomnia management (though addresses overlap), circadian rhythm disorders as primary diagnosis, and pediatric insomnia.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs (All Patients)": [
        {
          "item": "CBC (CPT 85025)",
          "rationale": "Exclude anemia contributing to fatigue and sleep disruption",
          "target": "Normal",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "CMP (CPT 80053)",
          "rationale": "Electrolyte abnormalities, renal/hepatic function; pre-treatment baseline",
          "target": "Normal",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "TSH (CPT 84443)",
          "rationale": "Hypothyroidism causes fatigue and hypersomnia; hyperthyroidism causes insomnia and anxiety",
          "target": "Normal (0.5-4.5 mIU/L)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Serum ferritin (CPT 82728)",
          "rationale": "Iron deficiency screen; low ferritin (<50 ng/mL) associated with restless legs syndrome causing sleep-onset and maintenance insomnia",
          "target": ">50 ng/mL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "AM cortisol (CPT 82533)",
          "rationale": "Screen for adrenal dysfunction; elevated cortisol causes insomnia; Cushing syndrome; HPA axis dysregulation in chronic insomnia",
          "target": "Normal AM cortisol (6-18 mcg/dL)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Urine drug screen (CPT 80307)",
          "rationale": "Exclude stimulant use, substance-related insomnia; caffeine, amphetamines, cocaine",
          "target": "Negative",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Extended Workup (Second-line)": [
        {
          "item": "Vitamin B12 (CPT 82607)",
          "rationale": "Deficiency associated with neuropathy, RLS, and sleep disruption",
          "target": ">400 pg/mL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Folic acid (CPT 82746)",
          "rationale": "Deficiency contributes to fatigue and neuropsychiatric symptoms",
          "target": ">4 ng/mL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Testosterone, free (CPT 84402)",
          "rationale": "Low testosterone in men associated with fatigue, poor sleep, and reduced sleep quality",
          "target": "Normal for age and sex",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Melatonin level (serum or salivary)",
          "rationale": "Assess dim light melatonin onset (DLMO) in suspected circadian component; low endogenous melatonin in elderly",
          "target": "Document; correlate with timing",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "HbA1c (CPT 83036)",
          "rationale": "Diabetes screening; neuropathic pain disrupts sleep; poorly controlled diabetes associated with insomnia",
          "target": "<5.7%",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "ESR (CPT 85652) / CRP (CPT 86140)",
          "rationale": "Screen for inflammatory or autoimmune conditions contributing to pain-related insomnia",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "Polysomnographic biomarkers (sleep microstructure analysis)",
          "rationale": "Research-level assessment of sleep architecture disruption; cyclic alternating pattern (CAP) rate",
          "target": "Document; correlate with clinical findings",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "HLA-DQB1*06:02 typing (CPT 81383)",
          "rationale": "If narcolepsy or central hypersomnolence is suspected in the differential",
          "target": "Document; supportive of narcolepsy if positive",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "CSF orexin / hypocretin-1",
          "rationale": "If narcolepsy is suspected; rule out central hypersomnolence disorder",
          "target": ">200 pg/mL normal; <=110 pg/mL suggests narcolepsy type 1",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "Sleep diary (minimum 2 weeks)",
          "timing": "Before any intervention; ongoing during treatment",
          "target": "Document sleep onset latency, WASO, total sleep time, sleep efficiency; identify patterns and contributing factors",
          "contraindications": "None",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "-"
        },
        {
          "item": "Actigraphy (CPT 95803) (2 weeks)",
          "timing": "Objective assessment of sleep-wake patterns; pre-treatment baseline",
          "target": "Confirm sleep diary; identify circadian pattern disruption; estimate total sleep time and sleep efficiency",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-"
        },
        {
          "item": "Insomnia Severity Index (ISI)",
          "timing": "Each visit; validated outcome measure",
          "target": "Baseline severity and treatment response; target ISI <8 (remission)",
          "contraindications": "None",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "-"
        },
        {
          "item": "Pittsburgh Sleep Quality Index (PSQI)",
          "timing": "Baseline and q3 months",
          "target": "Global sleep quality assessment; PSQI >5 indicates poor sleep quality",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-"
        },
        {
          "item": "Epworth Sleepiness Scale (ESS)",
          "timing": "Baseline to screen for excessive daytime sleepiness suggesting comorbid sleep disorder",
          "target": "ESS <=10 (normal); elevated ESS suggests OSA, narcolepsy, or other hypersomnia",
          "contraindications": "None",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "-"
        }
      ],
      "Extended": [
        {
          "item": "Polysomnography (PSG) (CPT 95810)",
          "timing": "If comorbid sleep disorder suspected (OSA, PLMD, RBD, nocturnal seizures); NOT for uncomplicated insomnia",
          "target": "Exclude OSA (AHI >5), PLMD (PLMS >15/hr), RBD, nocturnal seizures; document sleep architecture",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "EEG (awake and sleep) (CPT 95819)",
          "timing": "If nocturnal seizures or epileptiform activity suspected",
          "target": "Epileptiform discharges; focal slowing; sleep-related epilepsy patterns",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "MRI brain with and without contrast (CPT 70553)",
          "timing": "If structural cause suspected (TBI sequelae, hypothalamic lesion, neurodegenerative disease)",
          "target": "Rule out structural lesion, white matter disease, thalamic/hypothalamic pathology",
          "contraindications": "Per standard MRI contraindications",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "Home sleep testing (HSAT)",
          "timing": "If obstructive sleep apnea is suspected as contributing factor but in-lab PSG not feasible",
          "target": "AHI assessment; screen for moderate-severe OSA",
          "contraindications": "Cannot diagnose central apnea, PLMD, or RBD",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Advanced circadian rhythm testing (DLMO, core body temperature rhythm)",
          "timing": "If circadian rhythm component suspected",
          "target": "Document phase delay or advance; correlate with actigraphy and sleep diary",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Cognitive behavioral assessment (neurocognitive testing) (CPT 96132)",
          "timing": "If significant cognitive complaints; differentiate insomnia-related cognitive impairment from neurodegenerative process",
          "target": "Document attention, memory, processing speed deficits; correlate with sleep quality",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        }
      ]
    },
    "Treatment": {
      "Non-Pharmacologic Treatment (FIRST LINE — All Patients)": [
        {
          "item": "CBT-I (Cognitive Behavioral Therapy for Insomnia)",
          "route": "-",
          "indication": "First-line treatment for chronic insomnia; superior to pharmacotherapy for sustained benefit; effective in insomnia comorbid with neurological conditions",
          "dosing": {
            "doseOptions": [
              {
                "text": "N/A",
                "orderSentence": "CBT-I (Cognitive Behavioral Therapy for Insomnia) N/A -"
              }
            ],
            "route": "-",
            "instructions": "Individual or group format; 6-8 weekly sessions with trained therapist; includes cognitive restructuring, stimulus control, sleep restriction, relaxation training; digital CBT-I (e.g., Somryst/Pear) if in-person unavailable",
            "orderSentence": "CBT-I (Cognitive Behavioral Therapy for Insomnia) N/A -"
          },
          "contraindications": "Active untreated psychosis; severe cognitive impairment limiting engagement",
          "monitoring": "ISI score; sleep diary; treatment adherence",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sleep hygiene education",
          "route": "-",
          "indication": "Foundation for all insomnia management; address modifiable behavioral factors",
          "dosing": {
            "doseOptions": [
              {
                "text": "N/A",
                "orderSentence": "Sleep hygiene education N/A -"
              }
            ],
            "route": "-",
            "instructions": "Consistent sleep-wake schedule 7 days/week; bedroom dark, cool (65-68F), quiet; remove screens from bedroom; no clock-watching; avoid caffeine after noon; avoid alcohol within 4 hours of bedtime; no naps >20 minutes",
            "orderSentence": "Sleep hygiene education N/A -"
          },
          "contraindications": "None",
          "monitoring": "Adherence; sleep diary",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Stimulus control therapy",
          "route": "-",
          "indication": "Break conditioned association between bed/bedroom and wakefulness; re-establish bed as sleep cue",
          "dosing": {
            "doseOptions": [
              {
                "text": "N/A",
                "orderSentence": "Stimulus control therapy N/A -"
              }
            ],
            "route": "-",
            "instructions": "Go to bed only when sleepy; if unable to sleep within 20 minutes, leave bedroom and return only when sleepy; use bed only for sleep and intimacy; fixed wake time regardless of sleep obtained",
            "orderSentence": "Stimulus control therapy N/A -"
          },
          "contraindications": "May be challenging in hospitalized patients or those with mobility limitations",
          "monitoring": "Sleep diary; time to sleep onset",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sleep restriction therapy",
          "route": "-",
          "indication": "Increase sleep drive by consolidating sleep; improve sleep efficiency",
          "dosing": {
            "doseOptions": [
              {
                "text": "N/A",
                "orderSentence": "Sleep restriction therapy N/A -"
              }
            ],
            "route": "-",
            "instructions": "Restrict time in bed to match current total sleep time (minimum 5 hours); increase by 15-30 minutes weekly when sleep efficiency >85%; decrease by 15 minutes if efficiency <80%",
            "orderSentence": "Sleep restriction therapy N/A -"
          },
          "contraindications": "Bipolar disorder (risk of mania); epilepsy (sleep deprivation lowers seizure threshold); use with caution in these populations",
          "monitoring": "Sleep efficiency; daytime function; seizure frequency in epilepsy patients",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "First-Line Pharmacotherapy": [
        {
          "item": "Melatonin",
          "route": "PO",
          "indication": "Sleep onset insomnia; preferred in elderly and dementia; circadian rhythm support; minimal side effects and drug interactions",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg qHS",
                "orderSentence": "Melatonin 1 mg qHS PO"
              },
              {
                "text": "3 mg qHS",
                "orderSentence": "Melatonin 3 mg qHS PO"
              },
              {
                "text": "5 mg qHS",
                "orderSentence": "Melatonin 5 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 1-3 mg 30-60 minutes before desired bedtime; preferred in elderly and dementia patients due to favorable safety profile; may take 2-4 weeks for full effect; extended-release for sleep maintenance",
            "orderSentence": "Melatonin 1 mg qHS PO"
          },
          "contraindications": "Autoimmune conditions (theoretical); severe hepatic impairment",
          "monitoring": "Daytime sedation; headache; vivid dreams",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Suvorexant (Belsomra)",
          "route": "PO",
          "indication": "Insomnia with difficulty falling asleep and/or staying asleep; preferred in dementia-related insomnia; dual orexin receptor antagonist (DORA)",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg qHS",
                "orderSentence": "Suvorexant (Belsomra) 10 mg qHS PO"
              },
              {
                "text": "20 mg qHS",
                "orderSentence": "Suvorexant (Belsomra) 20 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10 mg within 30 minutes of bedtime; increase to 20 mg if tolerated and needed; effective for sleep onset and maintenance; take only if >=7 hours before planned awakening",
            "orderSentence": "Suvorexant (Belsomra) 10 mg qHS PO"
          },
          "contraindications": "Narcolepsy; concurrent strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin); severe hepatic impairment",
          "monitoring": "Daytime somnolence; sleep paralysis; hypnagogic hallucinations; suicidal ideation (rare)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Lemborexant (Dayvigo)",
          "route": "PO",
          "indication": "Insomnia with difficulty falling asleep and/or staying asleep; dual orexin receptor antagonist; may be better tolerated than suvorexant",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg qHS",
                "orderSentence": "Lemborexant (Dayvigo) 5 mg qHS PO"
              },
              {
                "text": "10 mg qHS",
                "orderSentence": "Lemborexant (Dayvigo) 10 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg within 30 minutes of bedtime; increase to 10 mg if needed; take only if >=7 hours before planned awakening; dose adjustment with moderate CYP3A4 inhibitors (max 5 mg)",
            "orderSentence": "Lemborexant (Dayvigo) 5 mg qHS PO"
          },
          "contraindications": "Narcolepsy; concurrent strong CYP3A4 inhibitors; severe hepatic impairment",
          "monitoring": "Daytime somnolence; sleep paralysis; headache; nightmares",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia with comorbid depression or anxiety; commonly used off-label for insomnia; good for sleep maintenance",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg qHS",
                "orderSentence": "Trazodone 25 mg qHS PO"
              },
              {
                "text": "50 mg qHS",
                "orderSentence": "Trazodone 50 mg qHS PO"
              },
              {
                "text": "100 mg qHS",
                "orderSentence": "Trazodone 100 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg at bedtime; titrate by 25 mg every 1-2 weeks; max 100 mg for insomnia indication; serotonin antagonist/reuptake inhibitor",
            "orderSentence": "Trazodone 25 mg qHS PO"
          },
          "contraindications": "Concurrent MAOIs; QT prolongation; severe hepatic impairment",
          "monitoring": "Orthostatic hypotension (especially elderly); priapism (rare); next-day sedation; QTc if cardiac risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ramelteon (Rozerem)",
          "route": "PO",
          "indication": "Sleep onset insomnia; melatonin receptor agonist (MT1/MT2); no abuse potential; safe in elderly; no DEA scheduling",
          "dosing": {
            "doseOptions": [
              {
                "text": "8 mg qHS",
                "orderSentence": "Ramelteon (Rozerem) 8 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "8 mg within 30 minutes of bedtime; do not take with or immediately after high-fat meal; no dose titration needed; onset within 30 minutes",
            "orderSentence": "Ramelteon (Rozerem) 8 mg qHS PO"
          },
          "contraindications": "Severe hepatic impairment; concurrent fluvoxamine (strong CYP1A2 inhibitor); history of angioedema to ramelteon",
          "monitoring": "Somnolence; dizziness; prolactin levels (with chronic use); reproductive hormone effects",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Second-Line / Neurological-Specific Pharmacotherapy": [
        {
          "item": "Gabapentin",
          "route": "PO",
          "indication": "Insomnia comorbid with neuropathic pain or restless legs syndrome; dual benefit for sleep and pain/RLS; enhances slow-wave sleep",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg qHS",
                "orderSentence": "Gabapentin 100 mg qHS PO"
              },
              {
                "text": "300 mg qHS",
                "orderSentence": "Gabapentin 300 mg qHS PO"
              },
              {
                "text": "600 mg qHS",
                "orderSentence": "Gabapentin 600 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100-300 mg at bedtime; titrate by 100-300 mg every 3-7 days; max 600 mg qHS for insomnia (higher doses for pain/RLS); renal dose adjustment required",
            "orderSentence": "Gabapentin 100 mg qHS PO"
          },
          "contraindications": "Hypersensitivity; severe renal impairment (adjust dose); respiratory depression risk with opioids",
          "monitoring": "Sedation; dizziness; peripheral edema; ataxia; renal function; suicidal ideation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Amitriptyline",
          "route": "PO",
          "indication": "Insomnia comorbid with chronic headache, neuropathic pain, or fibromyalgia; tricyclic antidepressant with strong sedating properties",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg qHS",
                "orderSentence": "Amitriptyline 10 mg qHS PO"
              },
              {
                "text": "25 mg qHS",
                "orderSentence": "Amitriptyline 25 mg qHS PO"
              },
              {
                "text": "50 mg qHS",
                "orderSentence": "Amitriptyline 50 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10 mg at bedtime; increase by 10-25 mg every 1-2 weeks; max 50 mg for insomnia; dual benefit for headache prophylaxis and neuropathic pain",
            "orderSentence": "Amitriptyline 10 mg qHS PO"
          },
          "contraindications": "Concurrent MAOIs; recent MI; cardiac conduction disease; narrow-angle glaucoma; urinary retention; AVOID in elderly/dementia (anticholinergic burden, Beers criteria)",
          "monitoring": "ECG if cardiac risk or dose >25 mg; anticholinergic effects (dry mouth, constipation, urinary retention); orthostatic hypotension; weight gain; cognitive effects in elderly",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Mirtazapine",
          "route": "PO",
          "indication": "Insomnia comorbid with poor appetite, weight loss, or depression; most sedating at lower doses (7.5-15 mg) due to predominant antihistaminic effect",
          "dosing": {
            "doseOptions": [
              {
                "text": "7.5 mg qHS",
                "orderSentence": "Mirtazapine 7.5 mg qHS PO"
              },
              {
                "text": "15 mg qHS",
                "orderSentence": "Mirtazapine 15 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 7.5 mg at bedtime; most sedating at 7.5-15 mg; higher doses (30-45 mg) are less sedating due to increased noradrenergic activity; weight gain is common",
            "orderSentence": "Mirtazapine 7.5 mg qHS PO"
          },
          "contraindications": "Concurrent MAOIs; hepatic impairment (reduce dose); renal impairment (reduce dose)",
          "monitoring": "Weight; metabolic panel (lipids, glucose); appetite; agranulocytosis (rare; monitor WBC if fever/infection); sedation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Doxepin (Silenor)",
          "route": "PO",
          "indication": "Sleep maintenance insomnia; FDA-approved at low doses (3-6 mg) for insomnia; selective histamine H1 antagonist at low dose",
          "dosing": {
            "doseOptions": [
              {
                "text": "3 mg qHS",
                "orderSentence": "Doxepin (Silenor) 3 mg qHS PO"
              },
              {
                "text": "6 mg qHS",
                "orderSentence": "Doxepin (Silenor) 6 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 3 mg within 30 minutes of bedtime; increase to 6 mg if needed; do not take within 3 hours of a meal; FDA-approved for insomnia at these low doses only",
            "orderSentence": "Doxepin (Silenor) 3 mg qHS PO"
          },
          "contraindications": "Concurrent MAOIs; narrow-angle glaucoma; urinary retention; severe hepatic impairment; use within 3 hours of meal",
          "monitoring": "Daytime sedation; nausea; upper respiratory infection (paradoxically common in trials)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Quetiapine",
          "route": "PO",
          "indication": "Insomnia with agitation in dementia or Parkinson's disease; also useful for insomnia with comorbid psychosis or severe anxiety; OFF-LABEL for insomnia",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg qHS",
                "orderSentence": "Quetiapine 25 mg qHS PO"
              },
              {
                "text": "50 mg qHS",
                "orderSentence": "Quetiapine 50 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 12.5-25 mg at bedtime; max 50 mg for insomnia; lowest effective dose; monitor metabolic effects; black box warning for mortality in elderly with dementia-related psychosis",
            "orderSentence": "Quetiapine 25 mg qHS PO"
          },
          "contraindications": "Concurrent QT-prolonging drugs; severe hepatic impairment; Lewy body dementia (may worsen motor symptoms; use with extreme caution)",
          "monitoring": "Metabolic panel (fasting glucose, lipids, weight) at baseline and q3 months; blood pressure; EPS; tardive dyskinesia; QTc; falls risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Medications to AVOID or Use with Extreme Caution in Neurological Patients": [
        {
          "item": "Benzodiazepines (e.g., temazepam, lorazepam, clonazepam)",
          "route": "PO",
          "indication": "AVOID in elderly, dementia, TBI, fall-risk patients; increased risk of falls, cognitive impairment, delirium, dependence, and respiratory depression",
          "dosing": {
            "doseOptions": [
              {
                "text": "AVOID",
                "orderSentence": "Benzodiazepines (e.g., temazepam, lorazepam, clonazepam) AVOID PO"
              }
            ],
            "route": "PO",
            "instructions": "Not recommended as first- or second-line for insomnia in neurological patients; if already prescribed, taper gradually over weeks to months to avoid withdrawal seizures",
            "orderSentence": "Benzodiazepines (e.g., temazepam, lorazepam, clonazepam) AVOID PO"
          },
          "contraindications": "Elderly (Beers criteria); dementia; TBI; myasthenia gravis; untreated OSA; history of substance abuse; respiratory insufficiency",
          "monitoring": "Cognitive function; falls; respiratory status; dependence; taper if discontinuing",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Zolpidem (Ambien)",
          "route": "PO",
          "indication": "AVOID in dementia, parasomnia-prone patients, and elderly; risk of complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating)",
          "dosing": {
            "doseOptions": [
              {
                "text": "AVOID",
                "orderSentence": "Zolpidem (Ambien) AVOID PO"
              }
            ],
            "route": "PO",
            "instructions": "Not recommended in neurological patients due to risk of complex sleep behaviors, falls, and cognitive impairment; if used, lowest dose only (5 mg women, 5-10 mg men)",
            "orderSentence": "Zolpidem (Ambien) AVOID PO"
          },
          "contraindications": "Dementia; history of parasomnias; elderly (Beers criteria); severe hepatic impairment; concurrent CNS depressants",
          "monitoring": "Complex sleep behaviors; next-day impairment; falls; cognitive function",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Diphenhydramine (Benadryl) / Hydroxyzine",
          "route": "PO",
          "indication": "AVOID in elderly; high anticholinergic burden; impairs cognition; paradoxical agitation in dementia; tolerance develops rapidly",
          "dosing": {
            "doseOptions": [
              {
                "text": "AVOID",
                "orderSentence": "Diphenhydramine (Benadryl) / Hydroxyzine AVOID PO"
              }
            ],
            "route": "PO",
            "instructions": "Not recommended for insomnia treatment in neurological patients; anticholinergic effects worsen cognition in dementia, cause urinary retention, and increase delirium risk",
            "orderSentence": "Diphenhydramine (Benadryl) / Hydroxyzine AVOID PO"
          },
          "contraindications": "Elderly (Beers criteria); dementia; narrow-angle glaucoma; BPH/urinary retention; concurrent anticholinergic medications",
          "monitoring": "Cognitive function; anticholinergic burden; falls; delirium",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Sleep medicine specialist for formal insomnia assessment, PSG if comorbid sleep disorder suspected, and CBT-I program coordination",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychology or psychiatry referral for CBT-I delivery; behavioral sleep medicine specialist preferred; digital CBT-I (Somryst/Pear Therapeutics) as alternative when in-person not available",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Neurology follow-up for underlying neurological condition management (TBI, dementia, MS, Parkinson's, epilepsy, stroke) as insomnia treatment is more effective when comorbid conditions are optimized",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychiatry referral if significant comorbid depression, anxiety, or PTSD contributing to insomnia; concurrent treatment improves outcomes for both conditions",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pain management referral if chronic pain is primary driver of sleep disruption; multimodal pain management improves sleep outcomes",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical/occupational therapy for TBI or stroke patients with insomnia to address activity level, daytime structure, and functional recovery",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient/Family Instructions": [
        {
          "item": "Insomnia is a treatable condition; behavioral interventions (CBT-I) are more effective than medications long-term and should be pursued as first-line therapy",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Maintain a consistent sleep-wake schedule 7 days per week including weekends; irregular schedules worsen insomnia by disrupting circadian rhythm",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Keep a daily sleep diary recording bedtime, estimated sleep onset time, number and duration of nighttime awakenings, final wake time, and subjective sleep quality; bring to all appointments",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Take sleep medications at the time prescribed and allow adequate time for sleep (at least 7 hours for most medications) to avoid next-day impairment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Do not increase medication doses without physician guidance; do not combine multiple sleep medications or add alcohol to aid sleep",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Seek urgent care if insomnia is accompanied by hallucinations, severe confusion, new neurological symptoms (weakness, numbness, speech difficulty), or suicidal thoughts",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Avoid screen use (phone, tablet, computer, TV) for at least 30-60 minutes before bedtime as blue light suppresses melatonin and stimulating content increases arousal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "If you cannot fall asleep within 20 minutes, get out of bed and do a quiet, non-stimulating activity in dim light until you feel sleepy, then return to bed (stimulus control)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Regular moderate exercise (30 minutes daily, 5 days/week) improves sleep quality; avoid vigorous exercise within 4 hours of bedtime as it may increase arousal",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Morning bright light exposure (30 minutes within 1 hour of waking) helps entrain circadian rhythm and improve sleep onset; especially important in dementia and TBI patients",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Caffeine cutoff by noon; caffeine half-life is 5-7 hours and even afternoon consumption significantly impairs sleep onset and reduces total sleep time",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Avoid alcohol as a sleep aid; although it promotes initial sleep onset, alcohol fragments sleep architecture, reduces REM sleep, and worsens insomnia in the second half of the night",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Maintain cool bedroom temperature (65-68 degrees F); core body temperature drop facilitates sleep onset",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Stress management techniques including progressive muscle relaxation, diaphragmatic breathing, and mindfulness meditation can reduce physiological hyperarousal that perpetuates insomnia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Weight management as obesity is associated with OSA, which commonly coexists with and exacerbates insomnia",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Limit daytime naps to 20 minutes maximum before 3:00 PM; longer or later naps reduce homeostatic sleep drive and worsen nighttime insomnia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Obstructive sleep apnea (OSA)",
      "features": "Snoring, witnessed apneas, obesity, morning headaches; may coexist with insomnia (COMISA); EDS more prominent than in pure insomnia",
      "tests": "PSG with respiratory scoring; AHI >5 events/hour; STOP-BANG questionnaire"
    },
    {
      "diagnosis": "Restless legs syndrome (RLS) / periodic limb movement disorder (PLMD)",
      "features": "Urge to move legs worse at rest and evening; sensory discomfort; PLMD causes arousals during sleep; low ferritin common",
      "tests": "Clinical history (IRLSSG criteria); serum ferritin; PSG showing PLMS >15/hour"
    },
    {
      "diagnosis": "Delayed sleep-wake phase disorder (DSWPD)",
      "features": "Cannot fall asleep until very late (2-6 AM); normal sleep duration once asleep; difficulty waking for early obligations; common in young adults",
      "tests": "Actigraphy; sleep diary showing consistent late sleep onset and late wake time; DLMO testing"
    },
    {
      "diagnosis": "Advanced sleep-wake phase disorder (ASWPD)",
      "features": "Sleepy in early evening; wakes very early (3-5 AM); common in elderly; total sleep time normal",
      "tests": "Actigraphy; sleep diary showing consistently early sleep onset and early wake time"
    },
    {
      "diagnosis": "REM sleep behavior disorder (RBD)",
      "features": "Dream enactment behavior; vocalizations during sleep; may cause sleep disruption; strong association with synucleinopathies (Parkinson's, DLB, MSA)",
      "tests": "PSG with REM without atonia; video documentation; screen for neurodegenerative disease"
    },
    {
      "diagnosis": "Medication-induced insomnia",
      "features": "Temporal relationship to medication initiation; common offenders: SSRIs, stimulants, beta-blockers, corticosteroids, theophylline, decongestants, levodopa",
      "tests": "Medication review; temporal correlation; trial of dose adjustment or timing change"
    },
    {
      "diagnosis": "Depression-related insomnia",
      "features": "Depressed mood, anhedonia, psychomotor changes; early morning awakening classic; terminal insomnia pattern; insomnia may be presenting symptom",
      "tests": "PHQ-9; psychiatric evaluation; insomnia often improves with depression treatment"
    },
    {
      "diagnosis": "Anxiety-related insomnia",
      "features": "Rumination, worry, hyperarousal at bedtime; sleep onset insomnia predominant; somatic symptoms of anxiety",
      "tests": "GAD-7; psychiatric evaluation; cognitive hyperarousal measures"
    },
    {
      "diagnosis": "PTSD-related insomnia",
      "features": "Nightmares, hypervigilance, avoidance behaviors; insomnia is core PTSD symptom; often treatment-resistant",
      "tests": "PCL-5; trauma history; PSG may show increased REM density and arousals"
    },
    {
      "diagnosis": "Pain-related sleep disruption",
      "features": "Chronic pain conditions (neuropathy, headache, fibromyalgia, arthritis) causing frequent arousals; pain worse at night; position-dependent",
      "tests": "Pain assessment scales; correlate sleep diary with pain diary; treat underlying pain"
    },
    {
      "diagnosis": "Nocturnal seizures",
      "features": "Stereotyped nocturnal events; sleep fragmentation; may not be recognized as seizures; consider in patients with epilepsy and new insomnia",
      "tests": "EEG (awake and sleep); video-EEG monitoring; PSG with expanded EEG montage"
    },
    {
      "diagnosis": "Insufficient sleep syndrome",
      "features": "Chronic voluntary sleep restriction due to work, social, or electronic media; resolves with adequate sleep opportunity",
      "tests": "Sleep diary and actigraphy showing chronic short sleep time; improvement with sleep extension"
    }
  ],
  "evidence": [
    {
      "recommendation": "CBT-I as first-line treatment for chronic insomnia in adults",
      "evidenceLevel": "Guideline, Strong recommendation",
      "source": "[Qaseem et al. Ann Intern Med 2016](https://pubmed.ncbi.nlm.nih.gov/27136449/)"
    },
    {
      "recommendation": "European guideline on insomnia diagnosis and treatment; strong recommendation for CBT-I; conditional for pharmacotherapy",
      "evidenceLevel": "Guideline, GRADE methodology",
      "source": "[Riemann et al. J Sleep Res 2017](https://pubmed.ncbi.nlm.nih.gov/28271506/)"
    },
    {
      "recommendation": "Suvorexant (DORA) improves sleep in patients with Alzheimer's disease insomnia without worsening cognition",
      "evidenceLevel": "Class I, Level A",
      "source": "[Herring et al. Ann Neurol 2020](https://pubmed.ncbi.nlm.nih.gov/31743476/)"
    },
    {
      "recommendation": "CBT-I produces sustained improvements in sleep onset latency and wake after sleep onset; meta-analysis of 20 RCTs",
      "evidenceLevel": "Class I, Level A (meta-analysis)",
      "source": "[Trauer et al. Ann Intern Med 2015](https://pubmed.ncbi.nlm.nih.gov/26054060/)"
    },
    {
      "recommendation": "AASM clinical practice guideline for pharmacologic treatment of chronic insomnia; recommendations for suvorexant, doxepin, ramelteon, and others",
      "evidenceLevel": "Guideline, systematic review",
      "source": "[Sateia et al. J Clin Sleep Med 2017](https://pubmed.ncbi.nlm.nih.gov/27998379/)"
    },
    {
      "recommendation": "CBT-I effective for insomnia following TBI; significant improvements in ISI and sleep diary parameters",
      "evidenceLevel": "Class II, Level B",
      "source": "[Ouellet et al. J Head Trauma Rehabil 2015](https://pubmed.ncbi.nlm.nih.gov/24495916/)"
    },
    {
      "recommendation": "Lemborexant efficacy and safety for insomnia disorder (SUNRISE 1 and 2 trials)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Rosenberg et al. JAMA Netw Open 2019](https://pubmed.ncbi.nlm.nih.gov/31880796/)"
    },
    {
      "recommendation": "Low-dose doxepin (3-6 mg) FDA-approved for sleep maintenance insomnia; selective H1 antagonism at low doses",
      "evidenceLevel": "Class I, Level A",
      "source": "[Krystal et al. Sleep 2011](https://pubmed.ncbi.nlm.nih.gov/21532951/)"
    },
    {
      "recommendation": "Gabapentin improves sleep in patients with restless legs syndrome and comorbid insomnia",
      "evidenceLevel": "Class I, Level A",
      "source": "[Winkelman et al. Sleep Med 2007](https://pubmed.ncbi.nlm.nih.gov/17368098/)"
    },
    {
      "recommendation": "Ramelteon efficacy for sleep onset insomnia; melatonin receptor agonist with no abuse potential",
      "evidenceLevel": "Class I, Level A",
      "source": "[Roth et al. Sleep Med 2006](https://pubmed.ncbi.nlm.nih.gov/16459136/)"
    },
    {
      "recommendation": "Insomnia as risk factor for cognitive decline and dementia in older adults",
      "evidenceLevel": "Class II, Level B",
      "source": "[Shi et al. Sleep Med Rev 2018](https://pubmed.ncbi.nlm.nih.gov/28890168/)"
    },
    {
      "recommendation": "AAN practice parameter on insomnia in neurological conditions; behavioral interventions recommended across neurological populations",
      "evidenceLevel": "Practice parameter",
      "source": "[Silber et al. Neurology 2004](https://pubmed.ncbi.nlm.nih.gov/15477546/)"
    }
  ],
  "monitoring": [
    {
      "item": "Insomnia Severity Index (ISI)",
      "frequency": "Baseline; every 4-6 weeks during active treatment; q3 months once stable",
      "action": "If ISI >=15 despite 6 weeks of treatment: reassess diagnosis, adherence to CBT-I, medication adjustment",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Sleep diary review",
      "frequency": "Every visit during active treatment",
      "action": "Adjust sleep restriction window; reinforce stimulus control; consider medication change",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Medication side effects",
      "frequency": "Each visit; focus on specific medication risks",
      "action": "Dose reduction, medication switch, or discontinuation",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Cognitive function (in elderly/dementia patients)",
      "frequency": "Baseline; every 6 months",
      "action": "Discontinue anticholinergic or sedating medications; reassess sleep medication choice",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Falls risk assessment (elderly patients)",
      "frequency": "Each visit if age >65 or neurological condition",
      "action": "Reduce sedating medications; physical therapy referral; environmental safety evaluation",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Quetiapine monitoring (if prescribed)",
      "frequency": "Baseline; q3 months: fasting glucose, lipid panel, weight",
      "action": "Lowest effective dose; consider alternative if metabolic changes; AIMS exam annually",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Trazodone monitoring (if prescribed)",
      "frequency": "Each visit; orthostatic BP at initiation",
      "action": "Dose reduction; add fluids/salt; discontinue if priapism occurs (urological emergency)",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Amitriptyline monitoring (if prescribed)",
      "frequency": "Baseline ECG if cardiac risk; each visit",
      "action": "Reduce dose; discontinue if QTc prolonged; switch to non-anticholinergic agent",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Depression/anxiety screening (PHQ-9, GAD-7)",
      "frequency": "Baseline; q3-6 months",
      "action": "Psychiatric referral; medication adjustment; intensify behavioral interventions",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Daytime function assessment",
      "frequency": "Each visit",
      "action": "Reassess treatment plan; evaluate for comorbid sleep disorders; consider PSG",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Outpatient management",
      "criteria": "Vast majority of insomnia patients; uncomplicated insomnia for CBT-I and/or pharmacotherapy; insomnia comorbid with stable neurological conditions"
    },
    {
      "disposition": "Admit for PSG",
      "criteria": "If comorbid OSA, PLMD, RBD, or nocturnal seizures suspected and outpatient PSG not feasible; schedule PSG night"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "Severe sleep deprivation with psychosis or delirium; TBI with severe insomnia and neurobehavioral dysregulation; acute neurological condition (stroke, MS relapse, status epilepticus) with significant sleep disruption requiring inpatient management"
    },
    {
      "disposition": "Transfer to higher level",
      "criteria": "Not typically applicable for insomnia; consider if severe insomnia-related delirium with agitation requires closer monitoring or if underlying neurological condition warrants ICU care"
    },
    {
      "disposition": "Sleep medicine referral",
      "criteria": "All patients with insomnia refractory to initial treatment (>=6 weeks CBT-I without improvement); suspected comorbid sleep disorder; need for PSG"
    },
    {
      "disposition": "Neurology referral",
      "criteria": "Insomnia with new neurological symptoms; suspected neurodegenerative disease; TBI-related insomnia; seizure-related sleep disruption"
    },
    {
      "disposition": "Psychiatry referral",
      "criteria": "Insomnia with significant comorbid depression, anxiety, PTSD, or substance use; suicidal ideation; medication management complexity"
    },
    {
      "disposition": "Follow-up frequency",
      "criteria": "Every 2-4 weeks during initial CBT-I or medication titration; every 3 months once stable; annually if in long-term remission"
    }
  ]
}